CRDF FY 2023 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$488,000+26.4% YoY

Gross Profit

$488,000100.0% margin

Operating Income

-$45M-9305.7% margin

Net Income

-$41M-8492.0% margin

EPS (Diluted)

$-0.93

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$82M

Total Liabilities

$12M

Stockholders' Equity

$70M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$488,000	$386,000	+26.4%
Gross Profit	$488,000	$386,000	+26.4%
Operating Income	-$45M	-$40M	-13.8%
Net Income	-$41M	-$39M	-7.1%